<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2018 [PPXK5GW761L0VL543HWD]. www.edgarsuite.com -->
<HEAD>
<TITLE>
 &nbsp;</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:10pt Times New Roman;margin-top:2.25pt;margin-bottom:0pt'><B>UNITED STATES </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Washington, D.C. 20549 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:1.5pt'><B>FORM 8-K </B></P>
<P align=center style='font:10pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>CURRENT REPORT</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Pursuant to Section 13 or 15(d)</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Of the Securities Exchange Act of 1934</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Date of Report (Date of earliest event reported): May 31, 2018</B></P>
<P align=center style='font:10pt Times New Roman;margin-top:18pt;margin-bottom:0pt'><B>MOUNT TAM BIOTECHNOLOGIES, INC. </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=middle><P style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt>&#160;</FONT></P>
</TD><TD valign=bottom><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>NEVADA</B></FONT></P>
</TD><TD valign=bottom><P align=center style='font:10pt Times New Roman;margin:0'><B>333-192060</B></P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>45-3797537</B></FONT></P>
</TD></TR>
<TR style=height:3.7pt><TD valign=middle><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>(State or other jurisdiction&#160;of</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.75pt'><FONT style=font-size:10pt><B>incorporation or organization)</B></FONT></P>
</TD><TD valign=middle><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>(Commission File Number)</B></FONT></P>
</TD><TD valign=middle><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>(I.R.S. Employer</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.75pt'><FONT style=font-size:10pt><B>Identification Number)</B></FONT></P>
</TD></TR>
</TABLE>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>7250 Redwood Boulevard, Suite 300</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='font-size:10pt;border-bottom:1px solid #000000'><B>Novato, California &nbsp;94925</B></FONT><FONT style=font-size:10pt><B> </B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>(425) 214-4079</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B> </B></FONT>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>(Address, including zip code, and telephone number, </B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>including area code, of registrant&#8217;s principal executive offices) </B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>N/A</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>(Former name or former address, if changed since last report)</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT style=font-family:Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt inherit;margin-top:0pt;margin-bottom:10pt;color:#212121;background-color:#FFFFFF'><FONT style='font-family:Times New Roman;color:#000000'>&#160;</FONT><FONT style='font-family:Times New Roman'>Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Emerging growth company &nbsp;&nbsp;&nbsp;&#9744;</P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;background-color:#FFFFFF'><FONT style=color:#212121>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</FONT>&#160; </P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><B>Item 5.03 </B></KBD><KBD style=margin-left:72pt></KBD><B>Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</B>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:72pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-72pt'><B>Item 5.07</B><FONT style=background-color:#FFFFFF><B> </B></FONT></KBD><B>Submission of Matters to a Vote of Security Holders.</B>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>On May 31, 2018, Mount Tam Biotechnologies, Inc. (the &#8220;<FONT style='border-bottom:1px solid #000000'>Company</FONT>&#8221;), filed a Certificate of Amendment to its Articles of Incorporation (the &#8220;<FONT style='border-bottom:1px solid #000000'>Certificate of Amendment</FONT>&#8221;) with the Nevada Secretary of State. Pursuant to the Certificate of Amendment, the Company increased its authorized shares of common stock from 100,000,000 to 200,000,000, par value $0.0001 per share (the &#8220;<FONT style='border-bottom:1px solid #000000'>Increase of Authorized Common Stock</FONT>&#8221;). The Certificate of Amendment became effective upon filing. The foregoing description of the Certificate of Amendment does not purport to be complete. A copy of the Certificate of Amendment is attached to this Current Report on Form&#160;8-K as Exhibit 3.1 and is incorporated herein by reference.</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000'>On May 30, 2018, the holders of a majority of the issued and outstanding voting securities of the Company, acting by written consent pursuant to Section 78.320 of the Nevada Revised Statutes and the Company&#8217;s bylaws, approved the following actions (the &#8220;<FONT style='border-bottom:1px solid #000000'>Actions</FONT>&#8221;):</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>(1) &nbsp;The Increase of Authorized Common Stock and the Certificate of Amendment.</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>(2) &nbsp;To permit, but not require, the Board of Directors of the Company to effectuate a reverse stock split of the Company&#8217;s common stock, par value $0.0001 per share, by a ratio of not less than one-for-ten (1:10) and not more than one-for-one thousand (1:1,000) (the &#8220;<FONT style='border-bottom:1px solid #000000'>Range</FONT>&#8221;), with the exact ratio to be set at a whole number within this Range as determined by the Company&#8217;s Board of Directors in its sole discretion at a date on or before July 1, 2019.</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>Specifically, holders of 28,525,427 shares of common stock, or 52.5% of the issued and outstanding voting securities of the Company, approved the Actions.</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><B>Item 7.01 </B></KBD><KBD style=margin-left:72pt></KBD><B>Regulation FD Disclosure.</B>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt'>On May 31, 2018, the Company issued a press release regarding the Actions, which is attached hereto as Exhibit 99.1.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>The press release included as Exhibit 99.1 will be deemed to be &#8220;furnished&#8221; rather than &#8220;filed,&#8221; pursuant to the rules of the Securities and Exchange Commission</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><B>Item 9.01 </B></KBD><KBD style=margin-left:72pt></KBD><B>Financial Statements and Exhibits. </B>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-72pt;margin-left:72pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-72pt;margin-left:72pt'>(d) Exhibits</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:397pt;margin-left:4.65pt><TR style=height:10.8pt><TD valign=middle style='width:63pt;white-space:nowrap;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'>Exhibit No.</P>
</TD><TD valign=middle style=width:29pt;white-space:nowrap><P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:305pt;white-space:nowrap;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'>Description</P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style='width:63pt;white-space:nowrap;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'>3.1</P>
</TD><TD valign=middle style=width:29pt;white-space:nowrap><P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:305pt;white-space:nowrap;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'><A href=mntm_ex3z1.htm style=text-decoration:none><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>Certificate of Amendment to Articles of Incorporation</FONT></A></P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:63pt;white-space:nowrap><P style='font:10pt Times New Roman;margin:0;color:#000000'>99.2</P>
</TD><TD valign=middle style=width:29pt;white-space:nowrap><P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:305pt;white-space:nowrap><P style='font:10pt Times New Roman;margin:0;color:#000000'><A href=mntm_ex99z1.htm style=text-decoration:none><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>Press Release dated May 31, 2018</FONT></A></P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0;text-indent:-72pt;margin-left:72pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SIGNATURES</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><B>MOUNT TAM BIOTECHNOLOGIES, INC.</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:50%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Date:&#160;&#160;&#160;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>May 31, 2018</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>By: </P>
</TD><TD valign=top style=white-space:nowrap><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>/s/ <I>Richard Marshak</I></FONT></P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Name: </P>
</TD><TD valign=bottom style=white-space:nowrap><P style='font:10pt Times New Roman;margin:0'>Richard Marshak</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Title:</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
</TD></TR>
</TABLE>
<P style='font:10pt Calibri;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "mntm_8k.htm", "description": "8-K", "secsgml_size_bytes": 16439}]
{"company-data": {"conformed-name": "Mount TAM Biotechnologies, Inc.", "cik": "0001589361", "assigned-sic": "2100", "irs-number": "453797537", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-192060", "film-number": "18874494"}, "business-address": {"street1": "7250 REDWOOD BLVD, SUITE 300", "city": "NOVATO", "state": "CA", "zip": "94945", "phone": "(425) 214-4079"}, "mail-address": {"street1": "7250 REDWOOD BLVD, SUITE 300", "city": "NOVATO", "state": "CA", "zip": "94945"}, "former-company": [{"former-conformed-name": "TabacaleraYsidron, Inc.", "date-changed": "20140206"}, {"former-conformed-name": "TABACALERAYSIDRON INC", "date-changed": "20140206"}, {"former-conformed-name": "TABACALERA YSIDRON INC", "date-changed": "20131016"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
Of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 31, 2018
MOUNT TAM BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA
333-192060
45-3797537
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)
7250 Redwood Boulevard, Suite 300
Novato, California  94925
(425) 214-4079
(Address, including zip code, and telephone number,
including area code, of registrant's principal executive offices)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Item 5.07
Submission of Matters to a Vote of Security Holders.
On May 31, 2018, Mount Tam Biotechnologies, Inc. (the "
Company
"), filed a Certificate of Amendment to its Articles of Incorporation (the "
Certificate of Amendment
") with the Nevada Secretary of State. Pursuant to the Certificate of Amendment, the Company increased its authorized shares of common stock from 100,000,000 to 200,000,000, par value $0.0001 per share (the "
Increase of Authorized Common Stock
"). The Certificate of Amendment became effective upon filing. The foregoing description of the Certificate of Amendment does not purport to be complete. A copy of the Certificate of Amendment is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference.
On May 30, 2018, the holders of a majority of the issued and outstanding voting securities of the Company, acting by written consent pursuant to Section 78.320 of the Nevada Revised Statutes and the Company's bylaws, approved the following actions (the "
Actions
"):
(1)  The Increase of Authorized Common Stock and the Certificate of Amendment.
(2)  To permit, but not require, the Board of Directors of the Company to effectuate a reverse stock split of the Company's common stock, par value $0.0001 per share, by a ratio of not less than one-for-ten (1:10) and not more than one-for-one thousand (1:1,000) (the "
Range
"), with the exact ratio to be set at a whole number within this Range as determined by the Company's Board of Directors in its sole discretion at a date on or before July 1, 2019.
Specifically, holders of 28,525,427 shares of common stock, or 52.5% of the issued and outstanding voting securities of the Company, approved the Actions.
Item 7.01
Regulation FD Disclosure.
On May 31, 2018, the Company issued a press release regarding the Actions, which is attached hereto as Exhibit 99.1.
The press release included as Exhibit 99.1 will be deemed to be "furnished" rather than "filed," pursuant to the rules of the Securities and Exchange Commission
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
3.1
Certificate of Amendment to Articles of Incorporation
99.2
Press Release dated May 31, 2018
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOUNT TAM BIOTECHNOLOGIES, INC.
Date:
May 31, 2018
By:
/s/
Richard Marshak
Name:
Richard Marshak
Title:
Chief Executive Officer